If you're apprehensive about getting an intravitreal injection for age-related macular degeneration (AMD), you're not alone. Ophthalmologist Monika Fleckenstein, MD, explains the procedure, how it can ...

The current standards of care involve using anti-VEGF agents, which selectively target extracellular VEGF. We've been doing this for years and those drugs do a good job, but there are limitations ...

Please provide your email address to receive an email when new articles are posted on . There are more options available than just the standard methods. Choices need to be made for every step of the ...

Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease ...

STOCKHOLM -- Two VEGF-targeting gene therapies for neovascular age-related macular degeneration (nAMD) substantially reduced treatment burden while preserving visual acuity, according to results ...

Dr. Amit Gupta, MD, FACS, Ophthalmologist, talks about the steps involved and potential side effects when getting an intravitreal injection. GOP wins major Supreme Court decision Grocery stores are ...

Please provide your email address to receive an email when new articles are posted on . Wearing gloves for intravitreal injections does not decrease the risk for endophthalmitis but does take up time ...

STOCKHOLM — Simple changes, like minimizing patient visits and reducing the use of nonsterile gloves, can make a big difference in the environmental impact of intravitreal injections without ...

CHICAGO — Specialists are losing money with every intravitreal injection they administer, regardless of the drug being injected, an investigator warns. Each injection we do costs $127.74 — $1.60 for ...

Aflibercept 8mg (0.07mL of 114.3mg/mL); per vial; soln for oph intravitreal inj; preservative-free. A single-dose glass vial containing one Eylea HD 8 mg (0.07 mL of a 114.3 mg/mL solution); or A vial ...

According to Aldeyra Therapeutics, a phase 2/3 trial of ADX-2191 in patients with retinitis pigmentosa is expected to begin in 2025. The Food and Drug Administration (FDA) has granted Fast Track ...